A comeback for checkpoint inhibition in multiple myeloma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Immunologic Combinations in Multiple Myeloma: Synergistic Stimulation with T cells and NK cells.International journal of biological sciences · 2026
   Review
2. The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma.Leukemia · 2025
   Article
3. Advancing CAR-T cell therapy: Insights into patient biology, leukapheresis, and cryopreservation.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
   Review
4. Targeting of the CD161 Inhibitory Receptor Enhances Bone-Marrow-Resident Memory CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
   Article
5. Glasgow Prognostic Score Serves as a Prognostic Factor of Clinical Outcome in Patients with Newly Diagnosed Multiple Myeloma.Journal of inflammation research · 2025
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.